NASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis → CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (From Banyan Hill Publishing) (Ad) Free STRO Stock Alerts $4.01 -0.14 (-3.37%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$3.99▼$4.1950-Day Range$3.27▼$5.6552-Week Range$2.01▼$6.13Volume388,410 shsAverage Volume616,897 shsMarket Capitalization$327.98 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Sutro Biopharma alerts: Email Address Sutro Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside211.7% Upside$12.50 Price TargetShort InterestHealthy2.38% of Shares Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment-0.06Based on 22 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.19) to ($3.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.57 out of 5 starsMedical Sector56th out of 921 stocksBiotechnology Industry1st out of 25 stocks 4.5 Analyst's Opinion Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSutro Biopharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sutro Biopharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.38% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sutro Biopharma has recently decreased by 10.55%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSutro Biopharma has received a 73.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sutro Biopharma is -0.70. Previous Next 1.1 News and Social Media Coverage News SentimentSutro Biopharma has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Sutro Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for STRO on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.90% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sutro Biopharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Sutro Biopharma are expected to decrease in the coming year, from ($3.19) to ($3.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sutro Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About Sutro Biopharma Stock (NASDAQ:STRO)Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Read More STRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STRO Stock News HeadlinesMay 16 at 7:31 AM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Athira Pharma (ATHA) and Taysha Gene Therapies (TSHA)May 16 at 6:56 AM | americanbankingnews.comSutro Biopharma, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.09) Per Share (NASDAQ:STRO)May 16 at 6:56 AM | americanbankingnews.comSutro Biopharma, Inc. to Post Q2 2024 Earnings of ($0.99) Per Share, HC Wainwright Forecasts (NASDAQ:STRO)May 16 at 5:04 AM | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Rating Reiterated by HC WainwrightMay 16 at 5:04 AM | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Rating Reiterated by WedbushMay 15, 2024 | markets.businessinsider.comBuy Rating on Sutro Biopharma: Promising Trials and Market Expansion Potential for LuveltaMay 14, 2024 | finanznachrichten.deSutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesMay 13, 2024 | msn.comSTRO Stock Earnings: Sutro Biopharma Misses EPS, Beats Revenue for Q1 2024May 13, 2024 | globenewswire.comSutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesMay 13, 2024 | finance.yahoo.comThe past three years for Sutro Biopharma (NASDAQ:STRO) investors has not been profitableMay 12, 2024 | americanbankingnews.comBank of America Initiates Coverage on Sutro Biopharma (NASDAQ:STRO)May 12, 2024 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Buy" from AnalystsMay 8, 2024 | markets.businessinsider.comExpert Outlook: Sutro Biopharma Through The Eyes Of 10 AnalystsMay 8, 2024 | msn.comB of A Securities Initiates Coverage of Sutro Biopharma (STRO) with Buy RecommendationMay 8, 2024 | msn.comBofA starts Sutro at buy, cites ovarian cancer drug candidateApril 30, 2024 | globenewswire.comSutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 TrialApril 17, 2024 | msn.comSutro Biopharma (STRO) Price Target Decreased by 6.45% to 13.15April 3, 2024 | markets.businessinsider.comSutro Biopharma Buy Rating Justified by Strategic Partnerships and Promising PipelineApril 2, 2024 | finance.yahoo.comSutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts SubstantiallyApril 2, 2024 | markets.businessinsider.comIpsen Secures Exclusive Global Rights Of Sutro Biopharma's STRO-003 ADC In Up To $900 Mln DealApril 2, 2024 | msn.comIpsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADCApril 2, 2024 | globenewswire.comSutro Biopharma Announces Pricing of $75 Million Underwritten OfferingApril 2, 2024 | marketwatch.comIpsen, Sutro Biopharma Enter Into Licensing Deal Valued at Up to $900 MlnApril 2, 2024 | globenewswire.comIpsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumorsApril 1, 2024 | msn.comPenny Stock Sutro Biopharma (NASDAQ:STRO): Intriguing Play for Biotech InvestorsSee More Headlines Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/19/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:STRO CUSIPN/A CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+211.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,790,000.00 Net Margins-74.61% Pretax Margin-63.06% Return on Equity-94.18% Return on Assets-27.38% Debt Debt-to-Equity RatioN/A Current Ratio4.46 Quick Ratio4.50 Sales & Book Value Annual Sales$153.73 million Price / Sales2.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.20 per share Price / Book3.34Miscellaneous Outstanding Shares81,790,000Free Float58,134,000Market Cap$327.98 million OptionableOptionable Beta1.09 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. William J. Newell J.D. (Age 66)CEO & Director Comp: $1.06MDr. Hans-Peter Gerber Ph.D. (Age 61)Chief Scientific Officer Comp: $575.83kDr. Anne Elizabeth Borgman-Hagey M.D. (Age 56)Chief Medical Officer Comp: $848.98kMs. Jane Chung R.Ph. (Age 53)President & COO Comp: $934.64kDr. James R. Swartz DScPh.D., Sc.D., FounderMr. Edward C. Albini M.B.A (Age 66)CFO & Secretary Comp: $596.4kDr. Venkatesh Srinivasan Ph.d. (Age 62)Chief Technical Operations Officer Mr. David Pauling J.D.M.A., General CounselMs. Linda A. Fitzpatrick (Age 67)Chief People & Communications Officer Comp: $595.79kDr. Nicki Vasquez Ph.D. (Age 61)Chief Portfolio Strategy & Alliance Officer More ExecutivesKey CompetitorsPoseida TherapeuticsNASDAQ:PSTXMonte Rosa TherapeuticsNASDAQ:GLUEMetagenomiNASDAQ:MGXAdaptimmune TherapeuticsNASDAQ:ADAPCoherus BioSciencesNASDAQ:CHRSView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Bought 729,239 shares on 5/16/2024Ownership: 1.713%California State Teachers Retirement SystemSold 3,776 shares on 5/16/2024Ownership: 0.010%Public Employees Retirement System of OhioBought 34,879 shares on 5/15/2024Ownership: 0.155%Price T Rowe Associates Inc. MDBought 3,578 shares on 5/15/2024Ownership: 0.029%Lazard Asset Management LLCBought 16,386 shares on 5/15/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions STRO Stock Analysis - Frequently Asked Questions Should I buy or sell Sutro Biopharma stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STRO shares. View STRO analyst ratings or view top-rated stocks. What is Sutro Biopharma's stock price target for 2024? 8 Wall Street analysts have issued 12 month price targets for Sutro Biopharma's stock. Their STRO share price targets range from $8.00 to $18.00. On average, they expect the company's stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 211.7% from the stock's current price. View analysts price targets for STRO or view top-rated stocks among Wall Street analysts. How have STRO shares performed in 2024? Sutro Biopharma's stock was trading at $4.29 at the beginning of the year. Since then, STRO stock has decreased by 6.5% and is now trading at $4.01. View the best growth stocks for 2024 here. When is Sutro Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our STRO earnings forecast. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) posted its quarterly earnings results on Monday, March, 25th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.82) by $1.24. The company earned $113.72 million during the quarter, compared to analyst estimates of $12.16 million. Sutro Biopharma had a negative net margin of 74.61% and a negative trailing twelve-month return on equity of 94.18%. What ETFs hold Sutro Biopharma's stock? ETFs with the largest weight of Sutro Biopharma (NASDAQ:STRO) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). What is William J. Newell's approval rating as Sutro Biopharma's CEO? 11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV). When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Sutro Biopharma's major shareholders? Sutro Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.84%), Baillie Gifford & Co. (2.96%), Acadian Asset Management LLC (1.93%), Jacobs Levy Equity Management Inc. (1.71%), Susquehanna Fundamental Investments LLC (0.20%) and Russell Investments Group Ltd. (0.18%). Insiders that own company stock include Brunilda Shtylla, Nicki Vasquez and William J Newell. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:STRO) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlacePOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.